Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Comparing intra-annular TAVR valves | Abbott's FreeStyle Libre makes an impact | Imaging & chest pain | The benefits of Barostim

News You Need to Know Today
Comparing intra-annular TAVR valves | Abbott's FreeStyle Libre makes an impact | Imaging & chest pain | The benefits of Barostim
Friday, May 16, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes

Each valve was associated with certain benefits, but one-year outcomes were largely similar. 

READ MORE >
Edwards Lifesciences SAPIEN 3 Ultra TAVR valve
Share on Twitter Share on Facebook Share on Linkedin

Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes

Share on Twitter Share on Facebook Share on Linkedin
Edwards Lifesciences SAPIEN 3 Ultra TAVR valve
Each valve was associated with certain benefits, but one-year outcomes were largely similar. 
READ MORE >

Abbott's FreeStyle Libre helps patients with diabetes stay out of the hospital

New data out of Sweden show that using Abbott's continuous glucose monitor technology is associated with a reduced risk of being hospitalized for cardiac complications. This was true for patients with and without a history of prior heart disease.

READ MORE >
Abbott FreeStyle Libre 3 CGM
Share on Twitter Share on Facebook Share on Linkedin

Abbott's FreeStyle Libre helps patients with diabetes stay out of the hospital

Share on Twitter Share on Facebook Share on Linkedin
Abbott FreeStyle Libre 3 CGM
New data out of Sweden show that using Abbott's continuous glucose monitor technology is associated with a reduced risk of being hospitalized for cardiac complications. This was true for patients with and without a history of prior heart disease.
READ MORE >

Imaging for chest pain: CT- and ICA-first strategies linked to similar long-term health status

These findings present additional evidence that invasive imaging tests are not necessarily more effective when it comes to evaluating patients for chest pain.

READ MORE >
Man Heart Attack
Share on Twitter Share on Facebook Share on Linkedin

Imaging for chest pain: CT- and ICA-first strategies linked to similar long-term health status

Share on Twitter Share on Facebook Share on Linkedin
Man Heart Attack
These findings present additional evidence that invasive imaging tests are not necessarily more effective when it comes to evaluating patients for chest pain.
READ MORE >

Duke specialists to detail the benefits of treating heart failure with Barostim

Specialists with Duke University Medical System will participate in a free webinar focused on their experience treating heart failure with the implantable Barostim technology from CVRx.

READ MORE >
CVRx banner
Share on Twitter Share on Facebook Share on Linkedin

Duke specialists to detail the benefits of treating heart failure with Barostim

Share on Twitter Share on Facebook Share on Linkedin
CVRx banner
Specialists with Duke University Medical System will participate in a free webinar focused on their experience treating heart failure with the implantable Barostim technology from CVRx.
READ MORE >

Featured Articles

Semaglutide works fast, protecting the heart before weight loss kicks in

"These results highlight semaglutide’s early action on decreasing major cardiovascular events," one cardiologist explained.

READ MORE >
Semaglutide (Wegovy) injector pen. Photo by Dave Fornell
Share on Twitter Share on Facebook Share on Linkedin

Semaglutide works fast, protecting the heart before weight loss kicks in

Share on Twitter Share on Facebook Share on Linkedin
Semaglutide (Wegovy) injector pen. Photo by Dave Fornell
"These results highlight semaglutide’s early action on decreasing major cardiovascular events," one cardiologist explained.
READ MORE >

Cardiology groups among the many voices asking Congress not to cut Medicaid

More than 40 U.S. healthcare organizations are urging Congress not to make sweeping Medicaid cuts that could result in approximately 7.6 million Americans losing health insurance.

READ MORE >
Kit Crancer, chair of the Radiology Business Management Association Radiology (RBMA) Patient Action Network, and senior vice president of public policy for Rayus, explains RBMA's concerns over how the Trump administration's $1 trillion in cuts to Medicaid will economically impact rural hospitals.
Share on Twitter Share on Facebook Share on Linkedin

Cardiology groups among the many voices asking Congress not to cut Medicaid

Share on Twitter Share on Facebook Share on Linkedin
Kit Crancer, chair of the Radiology Business Management Association Radiology (RBMA) Patient Action Network, and senior vice president of public policy for Rayus, explains RBMA's concerns over how the Trump administration's $1 trillion in cuts to Medicaid will economically impact rural hospitals.
More than 40 U.S. healthcare organizations are urging Congress not to make sweeping Medicaid cuts that could result in approximately 7.6 million Americans losing health insurance.
READ MORE >

PCI just as successful when patients have a history of TAVR—but there are some added risks

Strokes and bleeding complications are more likely when PCI patients have already undergone TAVR, according to a new analysis of ACC registry data.

READ MORE >
PCI interventional cardiology. The use of radial access during PCI procedures is increasing throughout the United States, and new data presented at the SCAI's annual meeting suggest that could be beneficial for patients. 
Share on Twitter Share on Facebook Share on Linkedin

PCI just as successful when patients have a history of TAVR—but there are some added risks

Share on Twitter Share on Facebook Share on Linkedin
PCI interventional cardiology. The use of radial access during PCI procedures is increasing throughout the United States, and new data presented at the SCAI's annual meeting suggest that could be beneficial for patients. 
Strokes and bleeding complications are more likely when PCI patients have already undergone TAVR, according to a new analysis of ACC registry data.
READ MORE >

Guest Commentary

It may not be easy, but it changes lives: Reframing myths of healthcare leadership

Leadership is not easy, but it is worth doing. According to one seasoned healthcare executive, the world needs more physicians to move into leadership positions.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

It may not be easy, but it changes lives: Reframing myths of healthcare leadership

Share on Twitter Share on Facebook Share on Linkedin
Leadership is not easy, but it is worth doing. According to one seasoned healthcare executive, the world needs more physicians to move into leadership positions.
READ MORE >

In Case You Missed It

A victory for early treatment: FDA approves first TAVR valves for asymptomatic severe aortic stenosis

The FDA has approved the balloon-expandable Sapien 3 TAVR platform from Edwards Lifesciences for treating asymptomatic severe aortic stenosis. This is the first time the agency has approved any TAVR technology to be used in asymptomatic patients. 

READ MORE >
Sapien 3 Ultra Resilia TAVR valves
Share on Twitter Share on Facebook Share on Linkedin

A victory for early treatment: FDA approves first TAVR valves for asymptomatic severe aortic stenosis

Share on Twitter Share on Facebook Share on Linkedin
Sapien 3 Ultra Resilia TAVR valves
The FDA has approved the balloon-expandable Sapien 3 TAVR platform from Edwards Lifesciences for treating asymptomatic severe aortic stenosis. This is the first time the agency has approved any TAVR technology to be used in asymptomatic patients. 
READ MORE >

Cardiologists share late-breaking TAVR data on first day of SCAI 2025

New TAVR data on SAPT vs. DAPT and prosthesis-patient mismatch among women were some of the many highlights of the conference's opening day.

READ MORE >
cardiologists heart doctors
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists share late-breaking TAVR data on first day of SCAI 2025

Share on Twitter Share on Facebook Share on Linkedin
cardiologists heart doctors
New TAVR data on SAPT vs. DAPT and prosthesis-patient mismatch among women were some of the many highlights of the conference's opening day.
READ MORE >

Latest EARLY TAVR data suggest it is time to update industry guidelines

Philippe Genereux, MD, principal investigator of EARLY TAVR, presented new data at ACC.25 showing intervening early on crossover patients with asymptomatic severe aortic stenosis led to better outcomes and a reduced stroke rate. 

READ MORE >
Philippe Genereux, MD, director of the structural heart program at Morristown Medical Center, principal investigator of the late-breaking EARLY TAVR trial, presented new data at ACC 2025 showing intervening earlier on patients with asymptomatic severe aortic stenosis leads to better outcomes.
Share on Twitter Share on Facebook Share on Linkedin

Latest EARLY TAVR data suggest it is time to update industry guidelines

Share on Twitter Share on Facebook Share on Linkedin
Philippe Genereux, MD, director of the structural heart program at Morristown Medical Center, principal investigator of the late-breaking EARLY TAVR trial, presented new data at ACC 2025 showing intervening earlier on patients with asymptomatic severe aortic stenosis leads to better outcomes.
Philippe Genereux, MD, principal investigator of EARLY TAVR, presented new data at ACC.25 showing intervening early on crossover patients with asymptomatic severe aortic stenosis led to better outcomes and a reduced stroke rate. 
READ MORE >

In Other News

FDA approves industry's first hands-free interventional X-ray system

Its voice recognition capabilities give providers the ability to maneuver the system and view images in real-time hands-free.

READ MORE >
uAngio AVIVA interventional X-ray system
Share on Twitter Share on Facebook Share on Linkedin

FDA approves industry's first hands-free interventional X-ray system

Share on Twitter Share on Facebook Share on Linkedin
uAngio AVIVA interventional X-ray system
Its voice recognition capabilities give providers the ability to maneuver the system and view images in real-time hands-free.
READ MORE >

NY Times revisits Nobel Prize winner’s prediction AI will render radiologists obsolete

In 2016, Geoffrey Hinton famously said, “People should stop training radiologists now,” believing it was “completely obvious” AI would outperform human rads within five years. 

READ MORE >
Man vs. Machine artificial intelligence AI. Replacing radiologists with AI.
Share on Twitter Share on Facebook Share on Linkedin

NY Times revisits Nobel Prize winner’s prediction AI will render radiologists obsolete

Share on Twitter Share on Facebook Share on Linkedin
Man vs. Machine artificial intelligence AI. Replacing radiologists with AI.
In 2016, Geoffrey Hinton famously said, “People should stop training radiologists now,” believing it was “completely obvious” AI would outperform human rads within five years. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

New heart failure device impresses | Cardiac amyloidosis in the spotlight | Experts agree: HFmrEF should not be ignored
Cardiology salaries outpace other specialties | A new TAVR technique | Cardiac amyloidosis in the spotlight | BP drug recalled
A new device warning after 3 deaths | AI predicts stroke risk | FDA clears intravascular imaging tech | IV fluids recalled
Top 10 most popular radiology video interviews this past month
Cardiac ablations in ASCs | Shockwave's new IVL catheter | Clopidogrel resistance | Sex dreams & the heart | AI for stroke risk
Heartflow sues AI rival Cleerly | Another win for opportunistic screening | Predicting TAVR outcomes | Key approvals for Abbott
Is TAVR too common among younger patients? | New-look heart failure device delivers | SCAI to study women in the cath lab

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …3
    • Page 4
    • Page 5
    • Page 6
    • Current page 7
    • Page 8
    • Page 9
    • Page 10
    • Page 11 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup